Clinical trials: Melanoma, Stage II
Advanced Malignancies
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v.
- Trial name
- NCT02608268
- Testing
- MBG453, PDR001, Decitabine
- Where
- 14 sites in United States, Canada and 7 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Mucosal Lentiginous Melanoma, Acral Melanoma
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Given the poor prognosis and limited treatment options available for patients with mucosal or acral/lentiginous melanomas who develop metastatic disease, genetic discoveries of KIT mutations in these cancers present the need to…
- Conditions
- Mucosal Lentiginous Melanoma, Acral Melanoma, Melanoma
- Trial name
- NCT00788775
- Testing
- Nilotinib
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Melanoma, Metastatic Kidney Cancer
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
Background: Natural killer (NK) cells are large lymphocytes (a type of white blood cell) that are important in the immune response to cancer.
- Trial name
- NCT00328861
- Testing
- Natural Killer (NK) Lymphocytes, IL-2, Cyclophosphamide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Ipilimumab and Local Radiation for Selected Solid Tumors
This pilot phase 1-2 trial studies the side effects and best of dose ipilimumab when given together with local radiation therapy and to see how well it works in treating patients with recurrent melanoma, non-Hodgkin lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01769222
- Testing
- Ipilimumab, Radiation therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Advanced Melanoma
Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)
In this study, participants with advanced melanoma will be treated with pembrolizumab (MK-3475) and their tumors and blood will be analyzed for changes related to pembrolizumab therapy.
- Trial name
- NCT03407170
- Testing
- pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC
The overall purpose of this research study is to find a better way to treat melanoma. The goals of this study are: 1. To measure the side effects of and find out how well patients tolerate the recMAGE-A3 + AS15 ASCI (MAGE-A3…
- Trial name
- NCT01437605
- Testing
- MAGE-A3 ASCI injections without Poly IC:LC, MAGE-A3 ASCI injections with Poly IC:LC
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation.
- Trial name
- TEAM (NCT01028222)
- Testing
- Nilotinib, DTIC
- Where
- 49 sites in United States, Argentina and 12 more
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
The purpose of this study is to assess the safety profile of vemurafenib, 960 mg, administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600 mutated advanced/metastatic melanoma.
- Trial name
- NCT01673854
- Testing
- Ipilimumab, Vemurafenib
- Where
- 14 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Melanoma (Skin)
Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery
RATIONALE: Pegylated arginine deiminase may stop the growth of tumor cells by taking away an amino acid needed for cell growth. PURPOSE: This phase II trial is studying how well pegylated arginine deiminase works in treating…
- Trial name
- NCT00450372
- Testing
- ADI-PEG-20, Pharmacology Studies
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Miami
Cancer
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
This was an open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2118436 and GSK1120212 in combination. This study was designed in four parts.
- Trial name
- NCT01072175
- Testing
- GSK2118436, GSK1120212
- Where
- 15 sites in United States, Australia
- Volunteers
- 430 people
- Sponsor
- Novartis Pharmaceuticals
Adult Solid Tumor, Adenocarcinoma of the Colon
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
RATIONALE: PD 0332991 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well PD 0332991 works in treating patients with…
- Conditions
- Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor
- Trial name
- NCT01037790
- Testing
- PD-0332991
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
The purpose of the study is to determine whether additional doses of ipilimumab have a positive effect on survival in the treatment of advanced melanoma that has progressed after successful initial treatment with ipilimumab.
- Trial name
- NCT01709162
- Testing
- Ipilimumab, Chemotherapy
- Where
- 17 sites in United States, Austria and 3 more
- Volunteers
- 31 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma
The purpose of this study is to determine if treatment with the autologous cellular vaccine, Melaxin, in combination with Bacillus Calmette-Guerin (BCG) injections is effective in Stage IV malignant melanoma.
- Trial name
- NCT00671554
- Testing
- Melaxin (autologous dendritoma vaccine) and BCG
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Prisma Health-Upstate
Melanoma
Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
The purpose of this study is to find out what effects an experimental drug, called interleukin 21 or rIL-21, will have on malignant melanoma and whether these effects look promising compared to dacarbazine.
- Trial name
- NCT01152788
- Testing
- rIL-21, Dacarbazine
- Where
- 19 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- NCIC Clinical Trials Group
Cancer, Melanoma
Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma
The study is a prospective phase II trial of radiation therapy concurrent with cisplatin chemotherapy in the treatment of locally advanced or metastatic melanoma in patients who are deemed to require radiation therapy by treating…
- Trial name
- NCT00707161
- Testing
- Radiation Therapy, Cisplatin, Surgical resection
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Utah
Recurrent Melanoma, Stage III Skin Melanoma
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
This phase II trial is studying how well MEK inhibitor AZD6244 works in treating patients with stage III or stage IV melanoma. MEK inhibitor AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for…
- Conditions
- Recurrent Melanoma, Stage III Skin Melanoma, Stage IV Skin Melanoma
- Trial name
- NCT00866177
- Testing
- Laboratory Biomarker Analysis, Selumetinib
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma, Advanced Melanoma
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
This is an open-label, non-randomized two arm Phase 2 study of intravenous nivolumab plus intravenous ipilimumab or intravenous relatlimab in patients with metastatic melanoma stratified by MHC-II expression.
- Conditions
- Metastatic Melanoma, Advanced Melanoma, Metastatic Melanoma Stratified by MHC-II Expression
- Trial name
- NCT03724968
- Testing
- Nivolumab, Relatlimab, Ipilimumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Elizabeth Davis
Uveal Melanoma
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
IMCgp100-102 is a Phase I/II study of the weekly intra-patient escalation dose regimen with IMCgp100 as a single agent in participants with metastatic uveal melanoma (mUM).
- Trial name
- NCT02570308
- Testing
- IMCgp100
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 146 people
- Sponsor
- Immunocore Ltd
Precancerous Condition, Stage 0 Melanoma
Lovastatin in Treating Patients At High Risk of Melanoma
The use of lovastatin may slow disease progression in patients at high risk of melanoma. It is not yet known whether lovastatin is more effective than a placebo in treating patients at high risk of melanoma.
- Conditions
- Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
- Trial name
- NCT00462280
- Testing
- lovastatin, biopsy, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Stage IV Melanoma
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
Primary: Phase Ib: To define the safety, tolerability and maximum tolerated dose (MTD) of lenvatinib administered in combination with dacarbazine.
- Trial name
- NCT01133977
- Testing
- Lenvatinib, Dacarbazine
- Where
- 27 sites in United States, Germany and 3 more
- Volunteers
- 97 people
- Sponsor
- Eisai Inc.